EYENOVIA ANNOUNCES PLANNED RETIREMENT OF LEAD INDEPENDENT DIRECTOR KEN LEE, JR.
NewsNEW YORK, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its own drug-device therapeutic programs…
Eyenovia to Participate in Multiple Medical Meetings in September
NewsNEW YORK—September 6, 2022—Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of late-stage microdose array print (MAP™) therapeutics, today announced that the company will be participating…
EYENOVIA ANNOUNCES APPOINTMENT OF OPHTHALMIC INDUSTRY VETERAN MICHAEL ROWE AS CHIEF EXECUTIVE OFFICER AND BOARD MEMBER
NewsAppointment of Mr. Rowe, Eyenovia’s current Chief Operating Officer, maintains continuity while bringing significant ophthalmic industry, operations and commercialization expertise to the CEO role
NEW YORK, July 27, 2022 (GLOBE NEWSWIRE)…
EYENOVIA PROVIDES MANUFACTURING UPDATE AND ANNOUNCES APPOINTMENT OF BREN KERN AS SVP OF MANUFACTURING AND OPERATIONS
NewsNew internal manufacturing capabilities to complement existing contract manufacturing relationships
NEW YORK, July 18, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a…
EYENOVIA ANNOUNCES APPOINTMENTS OF DR. ELLEN STRAHLMAN AND DR. RAM PALANKI AS NEW AND INDEPENDENT MEMBERS OF ITS BOARD OF DIRECTORS
News
EYENOVIA ANNOUNCES APPOINTMENTS OF DR. ELLEN STRAHLMAN AND DR. RAM PALANKI AS NEW AND INDEPENDENT MEMBERS OF ITS BOARD OF DIRECTORS
NEW YORK, July 07, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (Nasdaq: EYEN), an ophthalmic pharmaceutical…
Eyenovia CEO, CMO and Chairman Dr. Sean Ianchulev to Present at Eyecelerator @ American Society of Cataract and Refractive Surgery (ASCRS) 2022
NewsEyenovia CEO, CMO and Chairman Dr. Sean Ianchulev to Present at Eyecelerator @ American Society of Cataract and Refractive Surgery (ASCRS) 2022
Presentation to review historic issues related to glaucoma therapies and how these may be addressed…
Eyenovia Announces Poster Presentation at the 2022 American Society of Cataract and Refractive Surgery Annual Meeting
NewsApril 19, 2022 at 8:00 AM EDT
EYENOVIA ANNOUNCES POSTER PRESENTATION AT THE 2022 AMERICAN SOCIETY OF CATARACT AND REFRACTIVE SURGERY ANNUAL MEETING
Results of “SPEED” study confirm the speed of diagnostic effectiveness of a single microdose…
Eyenovia Announces Positive Study Results Demonstrating that its Optejet® Delivery Technology Reduces Conjunctival Cell Toxicity from Preserved Ophthalmic Solutions to a Level Comparable with Non-Preserved Solutions
News
Study conducted with Tufts Medical Center represents a breakthrough showing that Microdose Array Print (MAP™) technology can provide similar benefits of non-preserved medications
NEW YORK, March 15, 2022 (GLOBE NEWSWIRE) -- Eyenovia,…
Eyenovia Concludes Type A Meeting with FDA Related to MydCombi™ NDA Resubmission
NewsNo additional clinical work required; NDA resubmission anticipated in Q3 2022
NEW YORK, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose…
Eyenovia Announces Changes to the Board of Directors
NewsNEW YORK, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) therapeutics, today announced changes to its Board of Directors.
…